Rigel Pharmaceuticals Inc (Nasdaq:RIGL), a commercial stage biotechnology company focused on haematologic disorders and cancer, announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS).
R289 is a potent and selective dual inhibitor of IRAK1 and IRAK4 currently in Phase 1b clinical development for patients with lower-risk MDS who are relapsed or refractory to prior therapies.
Orphan Drug designation provides Rigel with potential benefits including tax credits, reduced FDA fees and seven years of market exclusivity following potential drug approval. This designation follows the previously granted Fast Track designation for R289 in this patient population.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024